The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3673-3680

  Lozano, Ester ^a,b   Joller, Nicole ^b   Cao, Yonghao ^a   Kuchroo, Vijay K ^b   Hafler, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD155 ANTIGEN; CD226 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; LENTIVIRUS VECTOR; MESSENGER RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELLS, CULTURED; CYTOKINES; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; PROTEIN BINDING; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84885167339     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300945     Document Type: Article

References (29)

1. Sharpe, A. H. 2009. Mechanisms of costimulation. Immunol. Rev. 229:5-11.
2. Joller, N., A. Peters, A. C. Anderson, and V. K. Kuchroo. 2012. Immune checkpoints in central nervous system autoimmunity. Immunol. Rev. 248:122-139.
3. Bour-Jordan, H., J. H. Esensten, M. Martinez-Llordella, C. Penaranda, M. Stumpf, and J. A. Bluestone. 2011. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol. Rev. 241:180-205.
4. Zhu, Y., S. Yao, and L. Chen. 2011. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34:466-478.
5. Maier, L. M., and D. A. Hafler. 2009. Autoimmunity risk alleles in costimulation pathways. Immunol. Rev. 229:322-336.
6. Cotsapas, C., B. F. Voight, E. Rossin, K. Lage, B. M. Neale, C. Wallace, G. R. Abecasis, J. C. Barrett, T. Behrens, J. Cho, et al; FOCiS Network of Consortia. 2011. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 7:e1002254.
7. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, T. McClanahan, T. Kitamura, J. Nicholl, G. R. Sutherland, L. L. Lanier, and J. H. Phillips. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4:573-581.
8. Pende, D., R. Castriconi, P. Romagnani, G. M. Spaggiari, S. Marcenaro, A. Dondero, E. Lazzeri, L. Lasagni, S. Martini, P. Rivera, et al. 2006. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107:2030-2036.
9. Lozano, E., M. Dominguez-Villar, V. Kuchroo, and D. A. Hafler. 2012. The TIGIT/CD226 axis regulates human T cell function. J. Immunol. 188:3869-3875.
10. Shibuya, K., J. Shirakawa, T. Kameyama, S. Honda, S. Tahara-Hanaoka, A. Miyamoto, M. Onodera, T. Sumida, H. Nakauchi, H. Miyoshi, and A. Shibuya. 2003. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J. Exp. Med. 198:1829-1839.
11. Hafler, J. P., L. M. Maier, J. D. Cooper, V. Plagnol, A. Hinks, M. J. Simmonds, H. E. Stevens, N. M. Walker, B. Healy, J. M. Howson, et al; International Multiple Sclerosis Genetics Consortium (IMSGC). 2009. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 10:5-10.
12. International Multiple Sclerosis Genetics Consortium (IMSGC). 2009. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 10:11-14.
13. Draghetti, C., C. Salvat, F. Zanoguera, M. L. Curchod, C. Vignaud, H. Peixoto, A. Di Cara, D. Fischer, M. Dhanabal, G. Andreas, et al. 2009. Functional wholegenome analysis identifies Polo-like kinase 2 and poliovirus receptor as essential for neuronal differentiation upstream of the negative regulator alphaB-crystallin. J. Biol. Chem. 284:32053-32065.
14. Pende, D., C. Bottino, R. Castriconi, C. Cantoni, S. Marcenaro, P. Rivera, G. M. Spaggiari, A. Dondero, B. Carnemolla, N. Reymond, et al. 2005. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 42:463-469.
15. Yu, X., K. Harden, L. C. Gonzalez, M. Francesco, E. Chiang, B. Irving, I. Tom, S. Ivelja, C. J. Refino, H. Clark, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10:48-57.
16. Joller, N., J. P. Hafler, B. Brynedal, N. Kassam, S. Spoerl, S. D. Levin, A. H. Sharpe, and V. K. Kuchroo. 2011. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 186:1338-1342.
17. Stanietsky, N., H. Simic, J. Arapovic, A. Toporik, O. Levy, A. Novik, Z. Levine, M. Beiman, L. Dassa, H. Achdout, et al. 2009. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 106:17858-17863.
18. Moffat, J., D. A. Grueneberg, X. Yang, S. Y. Kim, A. M. Kloepfer, G. Hinkle, B. Piqani, T. M. Eisenhaure, B. Luo, J. K. Grenier, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283-1298.
19. Dardalhon, V., A. S. Schubart, J. Reddy, J. H. Meyers, L. Monney, C. A. Sabatos, R. Ahuja, K. Nguyen, G. J. Freeman, E. A. Greenfield, et al. 2005. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J. Immunol. 175:1558-1565.
20. Tamura, T., O. Igarashi, A. Hino, H. Yamane, S. Aizawa, T. Kato, and H. Nariuchi. 2001. Impairment in the expression and activity of Fyn during differentiation of naive CD4+ T cells into the Th2 subset. J. Immunol. 167:1962-1969.
21. Ueda, A., L. Zhou, and P. L. Stein. 2012. Fyn promotes Th17 differentiation by regulating the kinetics of RORγt and Foxp3 expression. J. Immunol. 188:5247-5256.
22. Duda, P. W., M. C. Schmied, S. L. Cook, J. I. Krieger, and D. A. Hafler. 2000. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105:967-976.
23. Nabekura, T., K. Shibuya, E. Takenaka, H. Kai, K. Shibata, Y. Yamashita, K. Harada, S. Tahara-Hanaoka, S. Honda, and A. Shibuya. 2010. Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graftversus-host disease in mice. Proc. Natl. Acad. Sci. USA 107:18593-18598.
24. Masson, D., A. Jarry, B. Baury, P. Blanchardie, C. Laboisse, P. Lustenberger, and M. G. Denis. 2001. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49:236-240.
25. Tahara-Hanaoka, S., K. Shibuya, H. Kai, A. Miyamoto, Y. Morikawa, N. Ohkochi, S. Honda, and A. Shibuya. 2006. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 107:1491-1496.
26. Castriconi, R., A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64:9180-9184.
27. Chan, C. J., D. M. Andrews, N. M. McLaughlin, H. Yagita, S. Gilfillan, M. Colonna, and M. J. Smyth. 2010. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184:902-911.
28. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723.
29. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454.